Calcitonin gene-related peptide in migraine : from pathophysiology to treatment
Copyright © 2019 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved..
INTRODUCTION: It has been observed in recent years that levels of such molecules as calcitonin gene-related peptide (CGRP) and, to a lesser extent, the pituitary adenylate cyclase-activating peptide are elevated during migraine attacks and in chronic migraine, both in the cerebrospinal fluid and in the serum. Pharmacological reduction of these proteins is clinically significant, with an improvement in patients' migraines. It therefore seems logical that one of the main lines of migraine research should be based on the role of CGRP in the pathophysiology of this entity.
DEVELOPMENT: The Spanish Society of Neurology's Headache Study Group decided to draft this document in order to address the evidence on such important issues as the role of CGRP in the pathophysiology of migraine and the mechanism of action of monoclonal antibodies and gepants; and to critically analyse the results of different studies and the profile of patients eligible for treatment with monoclonal antibodies, and the impact in terms of pharmacoeconomics.
CONCLUSIONS: The clinical development of gepants, which are CGRP antagonists, for the acute treatment of migraine attacks, and CGRP ligand and receptor monoclonal antibodies offer promising results for these patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
---|---|
Enthalten in: |
Neurologia - 37(2022), 5 vom: 01. Juni, Seite 390-402 |
Sprache: |
Englisch |
---|
Weiterer Titel: |
CGRP en migraña: de la fisiopatología a la terapéutica |
---|
Beteiligte Personen: |
Santos-Lasaosa, S [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anticuerpos monoclonales |
---|
Anmerkungen: |
Date Revised 18.12.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.1016/j.nrl.2019.03.013 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM299386627 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM299386627 | ||
003 | DE-627 | ||
005 | 20231227133622.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.nrl.2019.03.013 |2 doi | |
028 | 5 | 2 | |a pubmed24n1231.xml |
035 | |a (DE-627)NLM299386627 | ||
035 | |a (NLM)31326215 | ||
035 | |a (PII)S0213-4853(19)30075-1 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Santos-Lasaosa, S |e verfasserin |4 aut | |
245 | 1 | 0 | |a Calcitonin gene-related peptide in migraine |b from pathophysiology to treatment |
246 | 3 | 3 | |a CGRP en migraña: de la fisiopatología a la terapéutica |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 18.12.2023 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Copyright © 2019 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved. | ||
520 | |a INTRODUCTION: It has been observed in recent years that levels of such molecules as calcitonin gene-related peptide (CGRP) and, to a lesser extent, the pituitary adenylate cyclase-activating peptide are elevated during migraine attacks and in chronic migraine, both in the cerebrospinal fluid and in the serum. Pharmacological reduction of these proteins is clinically significant, with an improvement in patients' migraines. It therefore seems logical that one of the main lines of migraine research should be based on the role of CGRP in the pathophysiology of this entity | ||
520 | |a DEVELOPMENT: The Spanish Society of Neurology's Headache Study Group decided to draft this document in order to address the evidence on such important issues as the role of CGRP in the pathophysiology of migraine and the mechanism of action of monoclonal antibodies and gepants; and to critically analyse the results of different studies and the profile of patients eligible for treatment with monoclonal antibodies, and the impact in terms of pharmacoeconomics | ||
520 | |a CONCLUSIONS: The clinical development of gepants, which are CGRP antagonists, for the acute treatment of migraine attacks, and CGRP ligand and receptor monoclonal antibodies offer promising results for these patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a Anticuerpos monoclonales | |
650 | 4 | |a CGRP | |
650 | 4 | |a Chronic migraine | |
650 | 4 | |a Gepantes | |
650 | 4 | |a Gepants | |
650 | 4 | |a Migraine | |
650 | 4 | |a Migraña | |
650 | 4 | |a Migraña crónica | |
650 | 4 | |a Monoclonal antibodies | |
700 | 1 | |a Belvís, R |e verfasserin |4 aut | |
700 | 1 | |a Cuadrado, M L |e verfasserin |4 aut | |
700 | 1 | |a Díaz-Insa, S |e verfasserin |4 aut | |
700 | 1 | |a Gago-Veiga, A |e verfasserin |4 aut | |
700 | 1 | |a Guerrero-Peral, A L |e verfasserin |4 aut | |
700 | 1 | |a Huerta, M |e verfasserin |4 aut | |
700 | 1 | |a Irimia, P |e verfasserin |4 aut | |
700 | 1 | |a Láinez, J M |e verfasserin |4 aut | |
700 | 1 | |a Latorre, G |e verfasserin |4 aut | |
700 | 1 | |a Leira, R |e verfasserin |4 aut | |
700 | 1 | |a Pascual, J |e verfasserin |4 aut | |
700 | 1 | |a Porta-Etessam, J |e verfasserin |4 aut | |
700 | 1 | |a Sánchez Del Río, M |e verfasserin |4 aut | |
700 | 1 | |a Viguera, J |e verfasserin |4 aut | |
700 | 1 | |a Pozo-Rosich, P |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Neurologia |d 2007 |g 37(2022), 5 vom: 01. Juni, Seite 390-402 |w (DE-627)NLM171204786 |x 2173-5808 |7 nnns |
773 | 1 | 8 | |g volume:37 |g year:2022 |g number:5 |g day:01 |g month:06 |g pages:390-402 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.nrl.2019.03.013 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 37 |j 2022 |e 5 |b 01 |c 06 |h 390-402 |